MKGAF News 158.0237 Merck Kgaa Dm 5 (MKGAF)
Post# of 273310
Posted On: 04/16/2014 3:53:48 PM
Merck Kgaa Dm 5 (MKGAF) 158.0237 $MKGAF
Merck KGaA Starts Study on Tecemotide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:55PM CDT
Oncothyreon announced that Merck KGaA commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25).
Merck KGaA and Auxogyn Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 4:00PM CDT
Merck KGaA entered into an exclusive license agreement with Auxogyn, Inc. for the Early Embryo Viability Assessment (Eeva) test.
Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:10PM CDT
Recently, Merck KGaA's biopharmaceutical division, Merck Serono, entered into a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, MA.
Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.
Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Avanir Reports Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 11, 8:37AM CST
Avanir reported 4Q13 net loss per share of 10 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents
Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.
Update on Threshold Pharma's TH-302 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 08, 10:20PM CDT
Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302
Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 01, 11:40AM CDT
The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada
Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 9:00PM CDT
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.
Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:24AM CDT
Merck KGaA reported first quarter 2013 earnings per American Depository Receipt (ADR) of $2.79, up 28.1% year over year.
Merck KGaA-CBRX Renew Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 11, 3:00PM CDT
Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years
Sanofi Reports Lemtrada Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 4:30PM CDT
Sanofi's subsidiary, Genzyme, announced interim data on Lemtrada.
Merck KGaA-BMY Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 21, 4:15PM CDT
Merck KGaA announced a deal with Bristol-Myers Squibb for the promotion of different formulations of Glucophage (metformin hydrochloride) in China.
Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 20, 4:00PM CDT
Merck KGaA recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin.
Threshold Cuts Loss, Misses Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 13, 9:00AM CDT
Threshold Pharmaceuticals Inc. reported fourth-quarter 2012 net loss per share of 10 cents, narrower than the Zacks Consensus Estimate of a loss of 12 cents.
Strong Quarter for Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 08, 9:40AM CST
Merck KGaA reported fourth quarter 2012 earnings per American Depository Receipt of $2.66, up 18.8% year over year.
Positive Data from BMRN's PKU-016 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 4:50PM CST
BioMarin announced positive results from the PKU-016 ASCEND study.
Merck KGaA Starts Study on Tecemotide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:55PM CDT
Oncothyreon announced that Merck KGaA commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25).
Merck KGaA and Auxogyn Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 4:00PM CDT
Merck KGaA entered into an exclusive license agreement with Auxogyn, Inc. for the Early Embryo Viability Assessment (Eeva) test.
Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:10PM CDT
Recently, Merck KGaA's biopharmaceutical division, Merck Serono, entered into a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, MA.
Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.
Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Avanir Reports Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 11, 8:37AM CST
Avanir reported 4Q13 net loss per share of 10 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents
Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.
Update on Threshold Pharma's TH-302 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 08, 10:20PM CDT
Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302
Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 01, 11:40AM CDT
The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada
Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 9:00PM CDT
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.
Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:24AM CDT
Merck KGaA reported first quarter 2013 earnings per American Depository Receipt (ADR) of $2.79, up 28.1% year over year.
Merck KGaA-CBRX Renew Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 11, 3:00PM CDT
Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years
Sanofi Reports Lemtrada Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 4:30PM CDT
Sanofi's subsidiary, Genzyme, announced interim data on Lemtrada.
Merck KGaA-BMY Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 21, 4:15PM CDT
Merck KGaA announced a deal with Bristol-Myers Squibb for the promotion of different formulations of Glucophage (metformin hydrochloride) in China.
Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 20, 4:00PM CDT
Merck KGaA recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin.
Threshold Cuts Loss, Misses Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 13, 9:00AM CDT
Threshold Pharmaceuticals Inc. reported fourth-quarter 2012 net loss per share of 10 cents, narrower than the Zacks Consensus Estimate of a loss of 12 cents.
Strong Quarter for Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 08, 9:40AM CST
Merck KGaA reported fourth quarter 2012 earnings per American Depository Receipt of $2.66, up 18.8% year over year.
Positive Data from BMRN's PKU-016 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 4:50PM CST
BioMarin announced positive results from the PKU-016 ASCEND study.
(0)
(0)